Abbott says it will go ahead with its plan to deal its generic pharmaceuticals line to Mylan for $5.3 billion and reports 3rd-quarter sales in line with expectations.
Valeant Pharmaceuticals says it might up the ante in its hostile takeover bid for Allergan as it reports higher-than-forecast profits for its 3rd quarter.
Actavis aims to head Valeant Pharmaceuticals off at the pass with a competing bid to acquire Allergan, people familiar with the matter tell Reuters.
Baxter International confirmed Cambridge, Mass., as the new R&D hub for Baxalta, the planned spinout of its biopharmaceuticals business.
Allergan is still looking to prevent Valeant Pharmaceuticals and Pershing Square from voting their shares in a December 18 shareholder meeting the company was forced to host.
A roundup of studies released at the annual Transcatheter Cardiovascular Therapies conference in Washington this week.
Here's a look at some of the news coming out of Washington at the 26th annual Transcatheter Cardiovascular Therapies conference this week: